ArrowMark Colorado Holdings’s Neurogene NGNE Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Sell	524,796 -52,694	-9%	-$1.02M	0.28%	112
2025 Q4	$11.9M	Sell	577,490 -18,349	-3%	-$457K	0.26%	112
2025 Q3	$10.3M	Buy	595,839 +10,442	+2%	+$210K	0.19%	132
2025 Q2	$8.75M	Buy	585,397 +143,806	+33%	+$2.26M	0.16%	135
2025 Q1	$5.17M	Sell	441,591 -7,010	-2%	-$122K	0.08%	174
2024 Q4	$10.3M	Buy	448,601 +62,136	+16%	+$2.31M	0.14%	135
2024 Q3	$16.2M	Hold	386,465	–	–	0.21%	107
2024 Q2	$14.1M	Sell	386,465 -51,073	-12%	-$1.8M	0.17%	116
2024 Q1	$22.3M	Sell	437,538 -87,991	-17%	-$2.94M	0.25%	94
2023 Q4	$10.2M	Buy	+525,529	New	+$7.53M	0.11%	143

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ArrowMark Colorado Holdings's NGNE Position: Q1 2026 in Review

ArrowMark Colorado Holdings reduced its Neurogene (NGNE) stake by 9.1% in Q1 2026, selling an estimated $1.02M and leaving 524,796 shares worth $10.6M. The position accounts for 0.28% of the portfolio, ranked #112.

ArrowMark Colorado Holdings first reported a position in NGNE in Q4 2023 and has held it in 10 quarters since. The position peaked at $22.3M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

ArrowMark Colorado Holdings held 524,796 shares of Neurogene worth $10.6M as of Q1 2026.
ArrowMark Colorado Holdings sold 52,694 Neurogene shares in Q1 2026, an estimated $1.02M.
Neurogene made up 0.28% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #112 holding.
ArrowMark Colorado Holdings first reported a position in Neurogene in Q4 2023 and has held it in 10 quarters since.
ArrowMark Colorado Holdings's Neurogene position peaked at $22.3M in Q1 2024.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.